JD5037, a peripherally-restricted CB1 inverse agonist, has also been demonstrated to reduce food intake, body weight, and adiposity in animal studies without established psychiatric side effects, showing improved potential for a therapeutic role in hepatic steatosis [41]. This evidence concerns the gene CNR1 and fatty liver disease.